8-K: Liquidia Reports Strong Preliminary 2025 YUTREPIA Sales

Liquidia Corporation announced preliminary full-year 2025 YUTREPIA net sales of $148.3 million and positive Q4 cash flow, signaling strong commercial momentum.

Summary

• Preliminary YUTREPIA net product sales reached approximately $90.1 million in Q4 2025 and $148.3 million for the full-year 2025.
• The company generated over $30 million of positive cash flow during Q4 2025.
• Cash and cash equivalents stood at approximately $190.7 million as of December 31, 2025.
• More than 2,800 unique patient prescriptions for YUTREPIA were received since its launch in June 2025 through December 2025.
• Over 2,200 patients started YUTREPIA treatment by December 2025, with an 85% conversion rate from prescription to patient start through November 2025.
• The total number of prescribers increased to approximately 750 through December 2025.
• Liquidia plans to expand its field sales team in 2026 to increase physician coverage in key territories.
• The company will continue investing in clinical development for YUTREPIA and L606 in 2026, including completing the ASCENT study and initiating multiple new open-label studies for various patient groups and indications (IPF, PPF, PH-COPD, systemic sclerosis associated Raynaud's phenomenon).
• An investigator-initiated trial evaluating YUTREPIA with Winrevrevair is also supported.
• Enrollment for L606's global pivotal Phase III Re-Spire study for PH-ILD patients is ongoing.

Sentiment

Score: 8

Explanation: The filing presents very strong preliminary financial results and commercial launch metrics for YUTREPIA, indicating rapid market adoption and positive cash flow. The company also outlines ambitious clinical development plans for future growth. The only cautionary notes are standard forward-looking statements and ongoing litigation, which are acknowledged risks but don't overshadow the positive operational performance.

Positives

• Strong preliminary full-year 2025 YUTREPIA net product sales of $148.3 million, with Q4 sales at $90.1 million.
• Significant quarter-over-quarter growth in net product sales at 74%.
• Generated over $30 million in positive cash flow during Q4 2025.
• Healthy cash and cash equivalents balance of approximately $190.7 million as of December 31, 2025.
• High patient adoption with over 2,800 unique prescriptions and 2,200 patient starts since June 2025 launch.
• Robust 85% conversion rate from prescription to patient start.
• Growing prescriber base, reaching approximately 750.
• Strategic plans to expand the sales team and invest in further clinical development for YUTREPIA and L606 across multiple indications.

Risks

• Preliminary financial results are unaudited and subject to final accounting adjustments, completion of internal control processes, and other developments.
• Ability to maintain YUTREPIA's approval and continued commercialization is subject to ongoing litigation with United Therapeutics seeking injunctive relief, which could block sales for PAH and/or PH-ILD.
• Forward-looking statements involve significant risks and uncertainties, and actual results could differ materially.
• Operating in a very competitive and rapidly changing environment with inherent industry risks.
• New risks emerge over time, and management cannot predict all risks or assess the full impact of all factors.

Future Outlook

Liquidia plans to build on its 2025 foundation by advancing clinical programs for YUTREPIA and L606 in 2026 to further differentiate them across current and potential future indications, including IPF, PPF, and PH-COPD, where significant unmet needs exist. The company believes these products have the potential to establish a new standard for inhaled prostacyclin therapy. They also plan to expand their field sales team in 2026.

Management Comments

• "2025 marked a transformational year for Liquidia, with the successful commercial launch of YUTREPIA across both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) patient populations."
• "We are encouraged by the continued momentum in adoption, which reflects strong execution by our team and growing physician confidence in YUTREPIA as a differentiated and increasingly preferred inhaled prostacyclin option."
• "Looking ahead to 2026, we are excited to build on this foundation by advancing clinical programs to further differentiate YUTREPIA and L606 across current and potential future indications, like IPF, PPF, and PH-COPD, where there remains a significant unmet need."
• "We believe YUTREPIA and L606 have the potential to establish a new standard for the use of inhaled prostacyclin as a critical therapeutic modality across these serious and progressive diseases."

Industry Context

Liquidia's YUTREPIA and L606 are positioned within the highly competitive and rapidly changing respiratory and vascular disease market, specifically targeting PAH and PH-ILD. The company aims to differentiate YUTREPIA as a preferred inhaled prostacyclin option against existing treatments like United Therapeutics' Tyvaso, Tyvaso DPI, and Remodulin, and Actelion's Uptravi. The expansion into new indications like IPF, PPF, and PH-COPD addresses significant unmet needs and broadens the market potential, aligning with a trend of developing targeted therapies for rare and progressive lung diseases. The support for an IIT with Winrevair (Merck) suggests potential for combination therapies, a common strategy in complex disease management.

Comparison to Industry Standards

• YUTREPIA is presented as a "differentiated and increasingly preferred inhaled prostacyclin option" compared to existing treatments like Tyvaso, Tyvaso DPI, and Uptravi.
• L606 is an investigational extended-release formulation aiming to enhance drug exposure over an extended period, potentially offering a more convenient dosing regimen than current inhaled treprostinil products.
• Liquidia's Treprostinil Injection is marketed as a first-to-file, fully substitutable generic for parenteral Remodulin, offering a lower price point while maintaining the same service and support.
• The company is exploring combination therapy with Winrevair, a product from Merck, to potentially reduce the need for parenteral prostacyclin therapy, indicating a focus on improving patient convenience and outcomes relative to current standards.

Legal Proceedings

• Ongoing litigation with United Therapeutics in the U.S. District Court for the District of Delaware and U.S. District Court for the Middle District of North Carolina.
• United Therapeutics is seeking injunctive relief, which could potentially block Liquidia's ability to continue selling YUTREPIA for one or both of PAH and PH-ILD.

Stakeholder Impact

• Shareholders: Positive impact due to strong preliminary sales, cash flow, and growth prospects, potentially leading to increased share value. However, ongoing litigation poses a significant risk.
• Patients (PAH/PH-ILD): Increased access to YUTREPIA as a "differentiated and increasingly preferred inhaled prostacyclin option," with ongoing clinical development aiming to expand treatment options and improve outcomes.
• Physicians: Growing confidence in YUTREPIA, supported by an expanding sales team and new clinical data, providing more treatment choices for their patients.
• Employees: Potential for growth and expansion, particularly with the planned increase in the field sales team.
• Competitors: Increased competition in the inhaled prostacyclin market, particularly for United Therapeutics.

Next Steps

• Report fully audited financial results for the year ended December 31, 2025, in February 2026.
• Participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-14, 2026, with a presentation by Dr. Roger Jeffs on January 14, 2026.
• Expand the field sales team in 2026 to increase physician coverage in key territories.
• Complete the ASCENT open-label study evaluating 52 weeks of treatment in PH-ILD patients.
• Initiate three new open-label, prospective, multicenter studies investigating YUTREPIA in PAH patients with inadequate response to other prostacyclin analogs, PH-ILD patients with inadequate response to Tyvaso/Tyvaso DPI, and IPF/PPF patients naive to inhaled treprostinil.
• Support an investigator-initiated trial (IIT) evaluating YUTREPIA in combination with Winrevair.
• Initiate a prospective, multicenter, open-label study of YUTREPIA in patients with systemic sclerosis associated Raynaud's phenomenon.
• Continue enrolling PH-ILD patients into Re-Spire, the global pivotal Phase III study for L606.

Key Dates

Recommendation

The preliminary financial results for YUTREPIA are exceptionally strong, demonstrating rapid market penetration and significant quarter-over-quarter sales growth shortly after launch. The generation of over $30 million in positive cash flow in Q4 2025 and a healthy cash balance of $190.7 million indicate robust financial health and operational efficiency. The high patient adoption rates and conversion from prescription to start underscore strong physician and patient confidence in the product. Furthermore, the company's aggressive clinical development pipeline for YUTREPIA and L606 across multiple indications suggests substantial future growth potential and a commitment to expanding its market footprint. While ongoing litigation with United Therapeutics presents a notable risk, the current operational momentum and financial performance are highly compelling, making Liquidia an attractive investment.

Keywords

Liquidia, LQDA, YUTREPIA, treprostinil, PAH, PH-ILD, pulmonary arterial hypertension, pulmonary hypertension, interstitial lung disease, L606, biopharmaceutical, drug launch, net sales, cash flow, clinical trials, respiratory diseases, vascular diseases, PRINT technology, SEC filing, 8-K